Menorrhagia from a haematologist's point of view. Part I: Initial evaluation

Haemophilia

Volumn 8, Issue 3, 2002, Pages 330-338

  Kouides, P A ^a  

^a Mary M Gooley Hemophilia Center   (United States)

Author keywords

Gynaecological complications; Hypothyroidism; Menorrhagia; Platlet disorders; Quality of life; von Willebrand disease

Indexed keywords

ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; CREATININE; DESMOPRESSIN ACETATE; FLUOXETINE; IRON; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PRAXIL; PROGESTERONE; RISTOCETIN; SEROTONIN UPTAKE INHIBITOR; THYROTROPIN; VON WILLEBRAND FACTOR;

ABSENTEEISM; ANAMNESIS; ARTICLE; BLEEDING; BLOOD CELL COUNT; CAPILLARY RESISTANCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EPISTAXIS; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; GYNECOLOGY; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; MEDICAL SPECIALIST; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION DISORDER; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THYROTROPIN BLOOD LEVEL; VON WILLEBRAND DISEASE; DIAGNOSIS, MEASUREMENT AND ANALYSIS; HEMATOLOGY; METHODOLOGY; PHYSICAL EXAMINATION; REVIEW;

FEMALE; HEMATOLOGY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MENORRHAGIA; PHYSICAL EXAMINATION;

EID: 0036588676     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00634.x     Document Type: Article

References (62)

1. Prentice A. Fortnightly review. Medical management of menorrhagia. BMJ 1999; 319: 1343-5.
2. Quick AJ. Menstruation in hereditary bleeding disorders. Obstetrics Gynecol 1966; 28: 37-48.
3. Lusher JM, McMillan CW. Severe factor VIII and factor IX deficiency in females. Am J Med 1978; 65: 637-48.
4. Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP. Results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thrombosis Haemostasis 1995; 74: 784-90.
5. Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 40-8.
6. Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998; 4: 836-41.
7. Rozeik C, Scharrer I. Defekt des von Willebrand faktor-proteins. Gynakologische und psychische probleme bei frauen mit von Willebrand-Syndrom. Gynakologische Geburtshilfe 1998; 3: 70-5.
8. Ragni MV, Bontempo FA, Cortese Hassett A. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313-7.
9. Kouides PA, Burkhart P, Phatak P et al. Gynecological and obstetrical morbidity in women with type I von Willebrand Disease. Results of a patient survey. Haemophilia 2000; 6: 643-8.
10. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrands disease or Factor XI deficiency. Br J Obstetrics Gynaecol 1998; 105: 314-21.
11. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstetrics Gynaecol 1991; 98: 909-18.
12. Noller KL, Bowie EJ, Kempers RD, Owen CA Jr. Von Willebrand's disease in pregnancy. Obstetrics Gynecol 1973; 41: 865-72.
13. Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257-60.
14. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.
15. Leissinger C, Becton D, Cornell C, Gill JC. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
16. Dilley A, Drews C, Miller C et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstetrics Gynecol 2001; 97: 630-6.
17. Economides DL, Kadir RA. Inherited bleeding disorders in obstetrics and gynaecology. Br J Obstetrics Gynaecol 1999; 106: 5-13.
18. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
19. Philipp CS, Dilley A, Miller CH et al. Platelet dysfunction and other hemostatic abnormalities among women with unexplained menorrhagia. Blood 2000; 96: abstract 254a.
20. Hahn L, Cederblad G, Rybo G, Pehrsson NG, Bengtsen KK. Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss. Br J Obstetrics Gynaecol 1976; 83: 974-80.
21. Bisht D, Gupta SC, Kaushik S, Ganguli G, Mital VP. Fibrinolysis in idiopathic menorrhagia. Indian J Pathol Microbiol 1991; 34: 200-2.
22. Kouides PA. Females with von Willebrand disese - 72 years as the silent majority. Haemophilia 1998; 4: 665-76.
23. Kouides PA. Obstetrical and gynaecological aspects of von Willebrand disease. Best Prac Res Clin Haematology 2001; 14: 381-99.
24. Chimbira TH, Anderson AB, Turnbull AC. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstetrics Gynaecol 1980; 87: 603-9.
25. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstetrics Gynecology 1984; 149: 788-93.
26. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstetrics Gynecol 1995; 85: 977-82.
27. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG: Int J Obstetrics Gynaecology 2000; 107: 320-2.
28. Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73: 367-71.
29. Mangal AK, Naiman SC. Oral contraceptives and von Willebrand's disease. Can Med Assoc J 1983; 128: 1274.
30. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
31. Blesing NE, Hambley H, McDonald GA. Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia. Postgraduate Med J 1990; 66: 474-6.
32. Krassas GE, Pontikides N, Kaltsas T et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol 1999; 50: 655-9.
33. Klein M, Barbe F, Kaminsky P, Duc M. Disorders of hemostasis in dysthyroidism. Pathologie Biologie 1993; 41: 268-75.
34. Coccia MR, Barnes HV. Hypothyroidism and acquired von Willebrand disease. J Adolescent Health 1991; 12: 152-4.
35. Michiels JJ, Schroyens W, Van der Berneman Z, PM. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thrombosis -Hemostasis 2001; 7: 113-5.
36. Bruising and thin skin in a 54-year-old woman. Am J Med 1985; 79: 101-10.
37. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 11-4.
38. Rosenoer VM, Tornay AS Jr. Drugs and the liver. Med Clinics North Am 1979; 63: 405-12.
39. Rozeik C, Scharrer I. Gynecological disorders and psychological problems in 184 women with von Willebrand disease. Haemophilia 1998; 4: abstract 293.
40. Bick RL. Platelet function defects: a clinical review. Seminars Thrombosis Hemostasis 1992; 18: 167-85.
41. Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Safety 1998; 18: 431-40.
42. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstetricia Gynecologica Scand 1966; 45: 320-51.
43. Montgomery RR, Coller BS. von Willebrand Disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Practice. Philadelphia: J.B. Lippincott Co., 1994: 134-68.
44. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-64.
45. Beck EA, Limoni C. Subnormal plasma von Willebrand factor (ristocetin cofactor) and iron deficiency anaemia in menstruating women. Thrombosis Haemostasis 1996; 75: 693.
46. Siegbahn A, Odlind V, Hedner U, Venge P. Coagulation and fibrinolysis during the normal menstrual cycle. Upsala J Med Sci 1989; 94: 137-52.
47. Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women. New England J Med 1980; 302: 1093-4.
48. Kouides PA, Phatak P, Sham RL et al. Adjusting the reference range of von Willebrand factor levels and Factor VIIIc level in relation to the menstrual cycle. Blood 1997; 90 (Suppl. 1): abstract 32a.
49. Werner EJ, Werner A, Gies L, Shults J, Adelman R. Variability of von Willebrand factor levels: a chronobiological study. Blood 1995; 87 (Suppl. 1): abstract 754a.
50. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thrombosis Haemostasis 1999; 82: 1456-61.
51. Onundarson PT, Gumundsdottir BR, Arnfinnsdottir AV, Kjeld M, Olafsson O. Von Willebrand factor does not vary during the normal menstrual cycle. Thrombosis Haemostasis 2001; 85: 183-4.
52. Miller CH, Dilley A, Richardson L, Evatt BL. Changes in von Willebrand factor and Factor VIII during the menstrual cycle. Blood 2000; 96: abstract 637a.
53. Small M, Lowe GD, Cameron E, Forbes CD. Contribution of the haematocrit to the bleeding time. Haemostasis 1983; 13: 379-84.
54. Fernandez F, Goudable C, Sie P et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-48.
55. Cohen AC, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235-41.
56. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170-9.
57. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thrombosis Haemostasis 2000; 84: 93-7.
58. Kerenyi A, Schlammadinger A, Ajzner E et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thrombosis Res 1999; 96: 487-92.
59. Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress-a study of 60 cases. Blood 1998; 91: 1325-31.
60. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thrombosis Haemostasis 1990; 63: 36-8.
61. Winkler UH. Menstruation extravascular fibrinolytic activity and reduced fibrinolytic capacity. Ann New York Acad Sciences 1992; 667: 289-90.
62. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 579-82.